QUIBIM_Welcome team1

Welcome our new team members!

We are very pleased to announce the last 4 incorporations to our QUIBIM Team. QUIBIM is in a continuous growth process, thanks to our customers, collaborators and partners like investors and funding agencies.

These new incorporations represent an important milestone for the company as they will support the development department and the business development unit to boost the company scale-up phase.

The new Quibimers:

One of the profiles incorporated comes from far away. Mr. Kabir Mahajan has a Master’s in Business Administration (MBA) from IESE Business School (Barcelona) and has studied Commerce and International Marketing from the University of Delhi (India). Prior to his MBA he was the Associate Director at Mahajan Imaging, India’s leading radiology and nuclear medicine services provider, and the co-founder of Mahajan Imaging Education and Research Academy. He has come to Valencia from New Delhi, India to support QUIBIM in strategy & business development as Chief Strategy Officer.

Also, we bring experience in the field of business development in hospitals and clinical trials with the incorporation of Mrs. Inmaculada Segarra Granell, a Pharmacist by the University of Valencia with a Master’s Degree in Development and Monitoring of National and International Clinical Trials. She previously worked for GLAXOSMITHKLINE during 15 years as account manager and as study coordinator in Hospital Universitario y Politecnico La Fe of Valencia in the Pediatrics. She has incorporated to QUIBIM team in the Area of Business Development looking for new business opportunities.

A solid science track record for our oncology pillar is the key value of Dr. Ismael Gonzalez Valverde, Chemical Engineer with a Master’s Degree in Bioengineering and a PhD in Biomedical Engineering. Previously, he was part of the M2BE team (Aragon Institute of Engineering Research) managing complex and interdisciplinary problems in the in silico modelling and biomechanics field. Ismael has experience in chemical and biological laboratories, as well as extensive programming knowledge in various programming languages and the administration of high-performance computing systems and Linux servers. Moreover, he is author of several scientific articles and communications to international congresses. He has joined QUIBIM team as the leading Image Analysis Scientist in oncology.

Last but not least, we also take care on incorporating talent with a great career ahead, young profiles who have significantly outperformed for their young age. This is the case of Mrs. Paula Moreno Ruiz, a Biomedical Engineer with a Master’s Degree in Biomedical Engineering by the Polytechnic University of Valencia. She has recently developed her Master Thesis about Medical Imaging Registration in the Vrije University of Brussels. She was working in a Research Center for Health Economics and Management (CIEGS) and in the Biomedical Imaging Research Group (GIBI230) of the Hospital Universitario y Politécnico La Fe as a scholarship. As she knows the company and this job environment, she has joined QUIBIM as the Team Coordinator supporting the Marketing, Communication, Administration and Management department.

Congratulations! We officially welcome them and hope they have a prosperous career in the company.


Meet our team

QUIBIM provides the platform for the GALEN Advanced Course organized by European School of Radiology

  • QUIBIM provided the software for the hands-on workshop activities, allowing a much more dynamic and interactive case discussion

QUIBIM was honored with the chance to participate in the last edition of the “GALEN Advanced Course on Oncologic Imaging of the Abdomen”. The event was organized by the European School of Radiology (ESOR), the educational initiative of the European Society of Radiology (ESR).

This course was aimed at senior residents, board-certified radiologists and fellows interested in abdominal oncologic imaging and focused on the application of the latest technical advancements and the new European guidelines for imaging.

ESOR_QUIBIM PrecisionQUIBIM provided the software for the hands-on workshop activities, allowing a much more dynamic and interactive case discussion. Based on our QUIBIM Precision® cloud Platform, this tool provides a powerful framework for the creation of new users, the uploading of imaging studies and relevant documentation and for the administration of the course.

Furthermore, the platform has been developed to provide lecturers with convenient features to share studies with students, visualize and edit them using our zero-footprint embedded DICOM Web Viewer and, most important, analyze the studies with any of the imaging biomarker plugins available at QUIBIM Precision®.

This event represents a great milestone for QUIBIM, as ESOR, with over 19.000 participants in more than 250 ESOR courses, has become the major provider of complementary radiological education in Europe and worldwide.



QUIBIM recibe la ayuda del IVACE – Proyectos de I+D de PYME (PIDI-CV)

QUIBIM ha obtenido financiación del Institut Valencià de Competitivitat Empresarial (IVACE) dentro del programa “Proyectos de I+D de PYME (PIDI-CV)” para la realización del proyecto “DESARROLLO DE ALGORITMOS DE INTELIGENCIA ARTIFICIAL PARA LA DETECCIÓN AUTOMATIZADA DE VÉRTEBRAS A PARTIR DE IMÁGENES DE TC EN OSTEOPOROSIS” con número de Expediente: IMITDA/2017/120.


El presente proyecto tiene el objetivo de desarrollar nuevas técnicas de análisis de imagen y algoritmos de Inteligencia Artificial (Machine Learning y Deep Learning) aplicados  a la caracterización de la columna vertebral a través de la segmentación automática de vértebras en imágenes de TC (tomografía computarizada), que permita el soporte al radiodiagnóstico en pacientes con osteoporosis. Para ello, se crea una nueva herramienta software de soporte que permita detectar e identificar automáticamente las vértebras en una imagen de TC. Una vez integrado este nuevo desarrollo como un nuevo módulo en nuestra plataforma Quibim Precission, estaremos en disposición de  caracterizar la microarquitectura ósea de cada una de las vértebras, realizar una evaluación de la misma y ofrecer un radiodiagnóstico avanzado capaz de aportar mayor información sobre la enfermedad ósea del paciente. 

La propuesta de valor para QUIBIM es contribuir con el presente proyecto a completar sus líneas de I+D, en concreto su línea  musculoesquelética. Así este proyecto ha supuesto la creación de un sistema especializado en la caracterización automática de la microarquitectura ósea vertebral, ofreciendo al radiólogo información cuantitativa sobre ésta, para mejorar la evaluación de tratamientos médicos y agilizar el control y seguimiento de pacientes con osteoporosis.

INTERVIEW | How Your Digital Twin Can Change Everything in Clinical Research

As technological advancements are rapidly increasing, the clinical research industry may not be too far away from doing in silico, or simulation trials which are truly virtual, and done of a healthy volunteer (or animal’s) digital model, otherwise known as a digital twin.  Imaging companies such as Quibim are best suited to pave the way forward for this next disruptive technology.  Not only will many animal and toxicity studies be able to be simulated, but can also theoretically be utilized as a pre-screening tool in order to proactively prevent SAE’s from occurring by running a simulation first and letting the patient and physician know what is likely to occur to patient if they enrolled into the study.  This may seem like science fiction, but so was the human genome project over a decade ago.

Outside of clinical research, just how patients are storing their own medical records for safekeeping and sharing with their healthcare providers, the same can in theory be possible when it comes to your digital twin that can be updated in real time, or perhaps every 5 years based on your MRI and other imaging results.

Ángel believes that phase 2-4 studies would still utilize real patients, but pre-clinical and toxicity studies can be completely simulated if the digital twin paradigm becomes commonplace in the research industry.  Not only will this mean faster clinical trials for animal and Phase 1 healthy volunteer studies, but it will allow for more sophisticated phase 2-3 pre-screening activities.

The in silico medicine movement will still require an opt-in from every patient that would want to: a.) have a digital twin and b.) share their digital twin with their healthcare providers.  Ángel believes that blockchain technology and the security and anonymity that is enables, will play a significant role in patients wanted to become involved with these types of technologies.  Our next episode will revolve around the topic of blockchain technology enabling technological innovations in clinical research and medicine in general.

QUIBIM se posiciona en el mercado americano analizando hábitats tumorales y enfermedades difusas hepáticas

Ha cerrado acuerdos con la compañía EnvoyAI y ha abierto oficina en Silicon Valley

QUIBIM sigue creciendo en el desarrollo de algoritmos de análisis de imágenes médicas basados en modelos biológicos y en inteligencia artificial. La compañía, que cerró el año 2017 con un crecimiento del 500% en sus métricas de negocio (número de análisis y facturación), ha avanzado con la expansión al mercado americano de sus algoritmos para cáncer y enfermedades difusas hepáticas. Entre los hitos más relevantes, además de la reciente apertura de oficina en Palo Alto (Silicon Valley, California), QUIBIM ha establecido una alianza con la empresa EnvoyAI, dedicada a la integración y distribución de algoritmos de inteligencia artificial para imágenes médicas. EnvoyAI fue adquirida el año 2016 por TeraRecon, empresa con un software de visualización radiológica que se encuentra actualmente instalado en el 85% de los hospitales de Estados Unidos.

Estos algoritmos de QUIBIM para el mercado americano, ahora mismo en proceso de certificación por la Food and Drug Administration (FDA), caracterizan tanto las diferentes subregiones o habitats internos de un tumor como analizan por biopsia virtual hepática las enfermedades difusas tipo esteatosis, sobrecarga de hierro, inflamación y fibrosis.

En el ámbito de la oncología, QUIBIM proporciona una metodología que extrae datos de textura, celularidad y proliferación vascular en los tumores, siendo aplicable en lesiones cerebrales, de mama, próstata, hígado y recto, entre los principales tumores sólidos. Esta metodología puede aplicarse a las imágenes de Resonancia Magnética y Tomografía Computarizada, proporcionando una información pronóstica sobre la evolución de los pacientes y su respuesta a los diferentes tratamientos.

En el ámbito de las enfermedades difusas hepáticas, QUIBIM proporciona un algoritmo para realizar una biopsia virtual hepática, sin dañar al paciente, a partir de las imágenes de Resonancia Magnética y extrayendo la proporción de grasa, concentración de hierro y proporciones de inflamación y fibrosis hepática. Este análisis es de especial relevancia para el estudio y seguimiento de la esteatohepatitis y la hemocromatosis, y en la evaluación de la historia natural y su modificación por el tratamiento en las hepatopatías crónicas y la cirrosis. Actualmente esta información se obtiene a partir de biopsias convencionales, lo que implica un riesgo para el paciente y un sesgo inherente al procedimiento dado que sólo se obtiene información del lugar de la punción, mientras que el algoritmo de QUIBIM permite obtener información de todo el hígado de manera segura.

En palabras de su CEO, el Dr. Ángel Alberich-Bayarri, resumiendo estos hitos “estamos en una fase muy intensa de la compañía y con un crecimiento significativo, y gracias al esfuerzo del equipo hemos podido acelerar varios hitos que teníamos previstos en fases más tardías, como por ejemplo la alianza con EnvoyAI, la solicitud a FDA y la apertura de oficina en EEUU. Los algoritmos que hemos seleccionado para este mercado aportan un valor diferencial que ya hemos podido verificar, recibiendo solicitudes desde algunos hospitales antes de iniciar acciones comerciales.”

QUIBIM es una empresa biotecnológica nacida en Valencia y está especializada en la extracción de información cuantitativa de las imágenes médicas radiológicas y de medicina nuclear, mediante técnicas originales y avanzadas de procesamiento computacional. Estos parámetros extraídos reciben el nombre de Biomarcadores de Imagen y aportan rasgos extraídos de las imágenes médicas, relacionadas con procesos biológicos normales, enfermedades o respuestas terapéuticas.

Además, el equipo ha desarrollado la plataforma QUIBIM Precision® de análisis de imágenes médicas en la nube, que puede instalarse en versiones privadas para hospitales y para compañías farmacéuticas que desarrollen ensayos clínicos. A partir de imágenes de rayos X, Ecografía, TAC, Resonancia Magnética o PET, QUIBIM es capaz de aplicar algoritmos avanzados de análisis con metodologías basadas en procesamiento por GPU (unidades de procesamiento gráfico), Machine Learning o Big Data. El software de QUIBIM permite aportar una mayor información en los diagnósticos y poder evaluar de forma temprana la respuesta a los tratamientos farmacológicos. La compañía fue seleccionada en 2017 para el programa SME Instrument Fase II de la Comisión Europea.


INTERVIEW | Is Quantitative Imaging Analysis in Clinical Research Cost Effective?

Today we are interviewing Jose García, Project Manager of Quibim’s clinical trials, as well as Ángel Alberich-Bayarri, CEO and founder of Quibim.

We have discussed the benefits of quantitative imaging analysis in previous episodes, but in this interview we are analyzing the cost effectiveness of this solution.  Ángel explained that if we take a long term holistic approach, we would be able to have a real time monitoring of the statistical analysis of the study.  This alone saves Sponsors potentially millions of dollars, but even beyond that, patient selection for future or current clinical trials can be more efficiently targeted when utilizing imaging biomarkers.

Jose also explained that the utilization of Quibim’s technology is a natural advancement in the evolution of how we conduct and analyze clinical research studies.  Although we are at the forefront of this revolution, costs are going to continue to drop as the required technology for real time quantitative analysis advances.  Jose used the analogy of dispersed light versus the precision of a laser beam and how Quibim’s capabilities more accurately reflect the latter.

In regards to the macro-analysis of cost saving measures, centralizing the process of qualitative and quantitative image reading services as it becomes increasingly quantitative due to the parameters being extracted.  Artificial intelligence and algorithms will also play a large role in the quantitative analysis and will assist the qualitative readings of humans, such as radiologists.  The more we can automate the quantitative process, the greater the cost savings are made available to the study sponsors.

Towards the end of the interview, we discussed in silico studies, where, by utilizing a “digital twin” of an actual study subject, sponsors could in theory create a simulated clinical trial and determine outcomes while reducing potential risk to human participants, specifically in phase 1 trials primarily.  Quibim is at the forefront of this movement, and we will focus on this topic in our next episode!


INTERVIEW | The Inefficiencies of Qualitative Imaging Analysis in Clinical Research

In this episode of Quibim Blog, CEO and founder Ángel Alberich-Bayarri sits down with Dan Sfera and discusses the differences between quantitative and qualitative imaging analysis when it comes to clinical research.  Some of the more common therapeutic indications that involve image analysis include: oncology, central nervous system disorder, and respiratory illnesses.  Ángel made a great analogy in this interview of artificial intelligence, the algorithms that power Quibim’s quantitative imaging capabilities, being similar to GPS when it comes to assisting drivers in navigating during their commutes.  Algorithms in imaging analysis are similar in the sense that they are tools to assist the imaging analysis readers (radiologists) in making quantitative diagnosis’ rather that the current industry standard of qualitative assessments.  That seems to be the key benefit of Quibim’s value proposition: taking a subjective diagnosis and adding a quantitative component to it in order to allow the clinicians to make better informed decisions.

INTERVIEW | Biomarker Imaging Analysis and Real Time Clinical Trial Capabilities

In this episode, Quibim CEO, Ángel Alberich-Bayarri discusses some of Quibim’s technological capabilities which makes real time clinical trial safety monitoring and efficacy assessments practical and possible.  Angel discusses the importance of analyzing biomarkers in the form of images and how this method can provide several advantages over the traditional blood biomarker analysis.  Join our mailing list to be notified of future webinars from Quibim!

INTERVIEW | A Clinical Research Entrepreneur’s Story and The Loss Of CRO Dominance In Research

Quibim founder Ángel Alberich-Bayarri and Dan Sfera discuss Quibim’s origins, and the entrepreneurial spirit which is necessary to have a successful startup company in the Life Sciences industry. Dan and Ángel also discuss the emergence of artificial intelligence in the clinical research space as well as how algorithms can help identify therapeutic effect of a particular treatment on a medical condition. The interview segways into the Precision Medicine Congress Conference just held in San Fransisco in January of 2018, an event which Ángel and Quibim were well received at due to their innovative technology and strong leadership team. Finally, the interview discusses the emergence of sophisticated and technologically capable vendors, such as Quibim itself, and how their emergence is allowing Sponsors to bring more of their research initiatives in house. It will certainly be an interesting clinical research landscape to keep an eye on this year and Quibim Blog will continue producing these interviews for you!

INTERVIEW| JP Morgan 2018 Healthcare Conference Recap: AI and Blockchain

Dan Sfera had the opportunity to interview Quibim founder, Ángel Alberich-Bayarri live on location in San Francisco, CA for the 2018 JP Morgan Healthcare Conference.  Not only was Quibim proud to showcase some of it’s imaging and algorithmic capabilities and technologies, but we were also able to network and collaborate with other vendors from within the life sciences industry in order to bring better clinical research solutions to our customers and patients!  For anyone not able to attend the conference in person, we hope that by watching this video we could give you a glimpse into some of the trending topics that is of interest to the greater pharmaceutical and medical device industries.  The two most popular topics that kept popping up at this year’s conference: Artificial Intelligence and Blockchain Technology. We hope to provide another recap after Quibim showcases at yet another industry conference also in San Francisco later this month. Stay tuned!